NCT02756988 (SPF Assay) is a NA clinical trial of Coppertone (BAY987704) in Sunscreening Agent, sponsored by Bayer.

Who is sponsoring NCT02756988?

NCT02756988 is sponsored by Bayer.

What drugs are being tested in NCT02756988?

Interventions in NCT02756988: Coppertone (BAY987704).

What condition does NCT02756988 study?

NCT02756988 studies Sunscreening Agent.

Is NCT02756988 still recruiting?

NCT02756988 is currently completed. Last updated 12 December 2018.

Last reviewed 2018-12-12 · How we verify

NCT02756988: SPF Assay

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

18615 - Sun Protection Factor Assay

Completed NA Last updated 12 December 2018

What this trial tests

NA trial testing Coppertone (BAY987704) in Sunscreening Agent in 10 participants. Completed in 21 October 2015.

Timeline

19 October 2015

Primary endpoint
21 October 2015

21 October 2015

Quick facts

Lead sponsor	Bayer
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	19 October 2015
Primary completion	21 October 2015
Estimated completion	21 October 2015
Sites	1 location across United States

Drugs / interventions tested

Coppertone (BAY987704) — full drug profile →

Conditions studied

Sunscreening Agent — all drugs for Sunscreening Agent →

Sponsor

Bayer — full company profile →

Who can join

Adults 18 to 70, any sex, with Sunscreening Agent. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the Sun Protection Factor efficacy on human skin.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Bayer trials

Trials by the same sponsor.

NCT05900388 — A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolis · not yet recruiting
NCT07490431 — An Observational Study to Learn More About How Elinzanetant is Used and How Well it Works for Women With Menopause Sympt · not yet recruiting
NCT05477953 — An Observational Pregnancy Safety Study in Women Who Were Exposed to the Drug Nifurtimox During Pregnancy to Learn About · not yet recruiting
NCT07192952 — A Study to Learn More About How Safe Finerenone is, When it is Taken for a Longer Time With Standard Treatment, in Child · Phase 3 · not yet recruiting
NCT07450599 — A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Befo · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT02756988 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Bayer
Last refreshed: 12 December 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT02756988.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing